Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird Sells 58,750 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 58,750 shares of Hims & Hers Health stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $21.04, for a total value of $1,236,100.00. Following the completion of the sale, the chief operating officer now directly owns 630,166 shares in the company, valued at $13,258,692.64. This represents a 8.53 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Melissa Baird also recently made the following trade(s):

• On Monday, October 7th, Melissa Baird sold 58,750 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.57, for a total value of $1,149,737.50.
• On Wednesday, September 4th, Melissa Baird sold 11,749 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.65, for a total value of $172,122.85.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $23.53 on Wednesday. The stock has a market cap of $5.14 billion, a PE ratio of 53.47 and a beta of 1.06. The firm has a 50-day moving average of $20.08 and a 200-day moving average of $19.07. Hims & Hers Health, Inc. has a 52-week low of $7.50 and a 52-week high of $30.44.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same period in the prior year, the firm earned ($0.04) EPS. The business’s revenue was up 77.1% on a year-over-year basis. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC raised its stake in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares in the last quarter. CWM LLC boosted its holdings in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth approximately $111,000. Finally, Quarry LP increased its holdings in shares of Hims & Hers Health by 91.0% during the third quarter. Quarry LP now owns 6,113 shares of the company’s stock worth $113,000 after purchasing an additional 2,913 shares during the period. 63.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Piper Sandler reiterated a “neutral” rating and issued a $21.00 price objective (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Bank of America downgraded shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their price objective for the stock from $32.00 to $18.00 in a research note on Thursday, November 14th. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Finally, Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $20.71.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.